Your browser is no longer supported

For the best possible experience using our website we recommend you upgrade to a newer version or another browser.

Your browser appears to have cookies disabled. For the best experience of this website, please enable cookies in your browser

We'll assume we have your consent to use cookies, for example so you won't need to log in each time you visit our site.
Learn more

Dementia drug shows promise for preventing Parkinson’s falls

  • Comment

A commonly prescribed dementia drug could hold the key to helping prevent debilitating falls for people with Parkinson’s disease, suggests UK research.

A study, published in the journal The Lancet Neurology, shows patients with Parkinson’s given the oral drug rivastigmine were 45% less likely to fall and were considerably steadier when walking, compared to those on a placebo.

“This takes us a step closer to improving the quality of life and finding better treatments for people with Parkinson’s”

Arthur Roach

Previous research suggests around 70% of people with Parkinson’s will fall at least once a year, with over a third experiencing falls repeatedly, resulting in fractures, broken bones and hospital admissions.

Dr Emily Henderson, from the University of Bristol and principal researcher on the new study, said: “With the degeneration of dopamine producing nerve cells, people with Parkinson’s often have issues with unsteadiness when walking.

“As part of the condition, they also have lower levels of acetylcholine, a chemical which helps us to concentrate – making it extremely difficult to pay attention to walking,” she said.

She added: “We already know that rivastigmine works to treat dementia by preventing the breakdown of acetylcholine, however our study shows for the first time that it can also improve regularity of walking, speed, and balance. This is a real breakthrough in reducing the risk of falls for people with Parkinson’s.”

The Bristol researchers studied 130 people with Parkinson’s who had fallen in the past year. Half were given rivastigmine capsules and the other half a placebo over an eight month period.

Dr Arthur Roach, director of research at Parkinson’s UK, which funded the study, said preventing falls and improving balance was the “biggest unmet” need for patients with the condition, other than finding a cure.

“This trial shows that there may be drugs already available, being used for other purposes, that can be tested to help treat Parkinson’s,” he said.

“This takes us a step closer to improving the quality of life and finding better treatments for people with Parkinson’s,” he added.

 

  • Comment

Have your say

You must sign in to make a comment

Please remember that the submission of any material is governed by our Terms and Conditions and by submitting material you confirm your agreement to these Terms and Conditions. Links may be included in your comments but HTML is not permitted.

Related Jobs